- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC Inhibitors in Acute Myeloid Leukemia
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 11, Pages 1794
Publisher
MDPI AG
Online
2019-11-14
DOI
10.3390/cancers11111794
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors
- (2019) Mei Han et al. Frontiers in Oncology
- Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results
- (2019) Matthew J. Wieduwilt et al. CLINICAL CANCER RESEARCH
- New drugs approved for acute myeloid leukemia (AML) in 2018
- (2019) Selin Kucukyurt et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
- (2018) Alice S. Mims et al. HAEMATOLOGICA
- Zinc binding groups for histone deacetylase inhibitors
- (2018) Lei Zhang et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes
- (2018) Ryan Lillico et al. JOURNAL OF PROTEOME RESEARCH
- Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia
- (2018) Stephan R. Bohl et al. Expert Review of Hematology
- A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
- (2018) Alice S. Mims et al. HAEMATOLOGICA
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC).
- (2018) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic and epigenetic determinants of AML pathogenesis
- (2018) Sheng F. Cai et al. SEMINARS IN HEMATOLOGY
- Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia
- (2018) Bowen Yan et al. LEUKEMIA
- Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation
- (2018) Nadja Blagitko-Dorfs et al. LEUKEMIA
- Subtype-specific regulatory network rewiring in acute myeloid leukemia
- (2018) Salam A. Assi et al. NATURE GENETICS
- High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects
- (2018) Xia Li et al. EBioMedicine
- Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials
- (2018) Hamid Sayar et al. LEUKEMIA RESEARCH
- The role of histone deacetylase inhibitors in metastatic breast cancer
- (2018) Bruna Zucchetti et al. BREAST
- Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells
- (2017) Giedrė Valiulienė et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Entinostat: a promising treatment option for patients with advanced breast cancer
- (2017) Roisin M Connolly et al. Future Oncology
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
- (2017) Vincent Ribrag et al. HAEMATOLOGICA
- Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials
- (2017) Richard F. Schlenk et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
- (2017) G Garcia-Manero et al. LEUKEMIA
- Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia
- (2017) Anilkumar Gopalakrishnapillai et al. LEUKEMIA RESEARCH
- Hypomethylating Agents as a Therapy for AML
- (2017) Claude Gardin et al. Current Hematologic Malignancy Reports
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
- (2017) Vincent Ribrag et al. HAEMATOLOGICA
- Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials
- (2017) Richard F. Schlenk et al. HAEMATOLOGICA
- Histone modifications patterns in tissues and tumours from acute promyelocytic leukemia xenograft model in response to combined epigenetic therapy
- (2016) Giedrė Valiulienė et al. BIOMEDICINE & PHARMACOTHERAPY
- The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR
- (2016) L. Zhou et al. BLOOD
- The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways
- (2016) Igor Hrgovic et al. BMC CANCER
- Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
- (2016) NAN LIU et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies
- (2016) Shabir Ahmad Ganai JOURNAL OF CHEMOTHERAPY
- Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells
- (2016) Yaping Sun et al. Journal of Innate Immunity
- Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells
- (2016) Yi Liao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia
- (2016) Norbert Vey et al. LEUKEMIA & LYMPHOMA
- Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin
- (2016) Carine Robert et al. LEUKEMIA RESEARCH
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
- (2016) I De Kouchkovsky et al. Blood Cancer Journal
- The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias
- (2016) Joanna Zabkiewicz et al. Oncotarget
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases
- (2016) Elizabeth E. Hull et al. Biomed Research International
- Acute Myeloid Leukemia: A Concise Review
- (2016) Jennifer Saultz et al. Journal of Clinical Medicine
- Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo
- (2015) Wenxiu Qi et al. CANCER BIOLOGY & THERAPY
- FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
- (2015) H.-Z. Lee et al. CLINICAL CANCER RESEARCH
- Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study
- (2015) E. M. Ocio et al. HAEMATOLOGICA
- Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia
- (2015) Franck Morschhauser et al. INVESTIGATIONAL NEW DRUGS
- Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cellsviachromatin remodelling
- (2015) Giedre Valiuliene et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia
- (2015) Jonathan How et al. LEUKEMIA & LYMPHOMA
- Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models
- (2015) Fernando F. Corrales-Medina et al. LEUKEMIA RESEARCH
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells
- (2015) Jing Yu et al. Oncotarget
- Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study
- (2015) E. M. Ocio et al. HAEMATOLOGICA
- Vorinostat-An overview
- (2015) AdityaKumar Bubna INDIAN JOURNAL OF DERMATOLOGY
- Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells
- (2014) Jurate Savickiene et al. ANTI-CANCER DRUGS
- Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
- (2014) M. Tassara et al. BLOOD
- A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
- (2014) Mark Kirschbaum et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
- (2014) Jean-Pierre Issa et al. CANCER
- Histone variants: key players of chromatin
- (2014) Burcu Biterge et al. CELL AND TISSUE RESEARCH
- Belinostat: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- (2014) Thomas Prebet et al. JOURNAL OF CLINICAL ONCOLOGY
- Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
- (2014) W Fiskus et al. LEUKEMIA
- A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
- (2014) L Zhou et al. LEUKEMIA
- Novel drugs for older patients with acute myeloid leukemia
- (2014) G Montalban-Bravo et al. LEUKEMIA
- Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
- (2014) W Fiskus et al. LEUKEMIA
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer
- (2014) Wen-Hsing Lin et al. PLoS One
- Dasatinib Accelerates Valproic Acid-Induced Acute Myeloid Leukemia Cell Death by Regulation of Differentiation Capacity
- (2014) Sook-Kyoung Heo et al. PLoS One
- Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
- (2014) E. Seto et al. Cold Spring Harbor Perspectives in Biology
- Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2014) P Tan et al. Blood Cancer Journal
- Driver mutations of cancer epigenomes
- (2014) David M. Roy et al. Protein & Cell
- Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
- (2014) Richard L Momparler et al. Clinical Epigenetics
- Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells
- (2013) Fiona Wightman et al. AIDS
- A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies
- (2013) Gert J. Ossenkoppele et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
- (2013) Guido Finazzi et al. BRITISH JOURNAL OF HAEMATOLOGY
- First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
- (2013) A. T. Brunetto et al. CLINICAL CANCER RESEARCH
- A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
- (2013) B. Holkova et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
- (2013) B. Venugopal et al. CLINICAL CANCER RESEARCH
- Peptide Based Macrocycles: Selective Histone Deacetylase Inhibitors with Antiproliferative Activity
- (2013) H. Rajak et al. CURRENT MEDICINAL CHEMISTRY
- Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
- (2013) R. B. Walter et al. HAEMATOLOGICA
- Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A
- (2013) Huong Thi Thanh Tran et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
- (2013) Mark H. Kirschbaum et al. LEUKEMIA & LYMPHOMA
- Histone acetylation: molecular mnemonics on the chromatin
- (2013) Johannes Gräff et al. NATURE REVIEWS NEUROSCIENCE
- Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms
- (2013) Gabriela Silva et al. PLoS One
- Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene-Dependent Model of Cytogenetically Normal Acute Myeloid Leukemia
- (2013) Joanne M. Ramsey et al. STEM CELLS
- Profile of panobinostat and its potential for treatment in solid tumors: an update
- (2013) Madhurima Anne et al. OncoTargets and Therapy
- Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
- (2013) Hanne Fredly et al. Clinical Epigenetics
- Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways
- (2012) Xue-Jie Jiang et al. CANCER LETTERS
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
- (2012) U. Banerji et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- (2012) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
- (2012) A Vilas-Zornoza et al. LEUKEMIA
- Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells
- (2012) Danian Nie et al. LEUKEMIA & LYMPHOMA
- Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors
- (2012) K. Pietschmann et al. MOLECULAR CANCER THERAPEUTICS
- The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
- (2012) V Novotny-Diermayr et al. Blood Cancer Journal
- Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells
- (2011) Ai-Hua Wang et al. ANNALS OF HEMATOLOGY
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim
- (2011) Yun Dai et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
- (2011) R. B. Walter et al. HAEMATOLOGICA
- Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
- (2011) E McCormack et al. LEUKEMIA
- Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia hasin vitrobut limited clinical activity
- (2011) Steven Lane et al. LEUKEMIA & LYMPHOMA
- Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells
- (2011) Chie Nishioka et al. LEUKEMIA RESEARCH
- Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C
- (2011) M.T. Corsetti et al. LEUKEMIA RESEARCH
- Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2011) Yoshihiro Minamiya et al. LUNG CANCER
- Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue
- (2011) V. Novotny-Diermayr et al. MOLECULAR CANCER THERAPEUTICS
- Unknown
- (2011) Antonio Furlan et al. MOLECULAR MEDICINE
- The genomic complexity of primary human prostate cancer
- (2011) Michael F. Berger et al. NATURE
- Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
- (2011) Luca A. Petruccelli et al. PLoS One
- The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy
- (2010) Yue Wei et al. Autophagy
- Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists
- (2010) A. Mandawat et al. BLOOD
- A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
- (2010) Alessandro Rambaldi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
- (2010) Warren Fiskus et al. CANCER BIOLOGY & THERAPY
- Inside HDAC with HDAC inhibitors
- (2010) Philippe Bertrand EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells
- (2010) Jie Chen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia – a report of five cases
- (2010) Hanne Fredly et al. Hematology
- Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor
- (2010) David Moffat et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemical phylogenetics of histone deacetylases
- (2010) James E Bradner et al. Nature Chemical Biology
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
- (2010) Julia M. Wagner et al. Clinical Epigenetics
- Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells
- (2009) C. P. Miller et al. BLOOD
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
- (2009) K. Shiozawa et al. CLINICAL CANCER RESEARCH
- An operational definition of epigenetics
- (2009) S. L. Berger et al. GENES & DEVELOPMENT
- A phase 2 study of vorinostat in acute myeloid leukemia
- (2009) E. W. Schaefer et al. HAEMATOLOGICA
- The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair
- (2009) P Maiso et al. LEUKEMIA
- Multiple roles of HDAC inhibition in neurodegenerative conditions
- (2009) De-Maw Chuang et al. TRENDS IN NEUROSCIENCES
- Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
- (2008) G. Garcia-Manero et al. BLOOD
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
- (2008) Olaia Martínez-Iglesias et al. Clinical & Translational Oncology
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo
- (2008) W. Weichert et al. CLINICAL CANCER RESEARCH
- Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes
- (2008) V. M. Klimek et al. CLINICAL CANCER RESEARCH
- Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells
- (2008) W. Fiskus et al. CLINICAL CANCER RESEARCH
- An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1
- (2008) Christin L. Hanigan et al. GASTROENTEROLOGY
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21 waf1 promoter in acute myelogenous leukemia cell
- (2008) C Nishioka et al. LEUKEMIA
- Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells
- (2008) C Nishioka et al. LEUKEMIA
- MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells
- (2008) Chie Nishioka et al. LEUKEMIA RESEARCH
- Combinatorial patterns of histone acetylations and methylations in the human genome
- (2008) Zhibin Wang et al. NATURE GENETICS
- The many roles of histone deacetylases in development and physiology: implications for disease and therapy
- (2008) Michael Haberland et al. NATURE REVIEWS GENETICS
- Epigenetics in Acute Myeloid Leukemia
- (2008) Christoph Plass et al. SEMINARS IN ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started